Skip to main content

Organizational Ethics and the High Cost of Medicines

HEC Forum volume 12, pages 303–310 (2000)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

39,95 €

Price includes VAT (Netherlands)

REFERENCES

  1. Dembling B, Chen DT, Vachon L. Life expectancy and causes of death in a population treated for serious mental illness. Psychiatric Services. 1999; 50:1036-42.

    Google Scholar 

  2. Black DW, Warrach KR, Winokur G. Excess mortality among psychiatric patients: The Iowa record-linkage study. Journal of the American Medical Association. 1985; 253:58-61.

    Google Scholar 

  3. Lawrie SM, Parsons C, Patrick J, et al. A controlled trial of general practitioners' attitudes to patients with schizophrenia. Health Bulletin (Edinburgh). 1996; 54:201-03.

    Google Scholar 

  4. Rochefort DA. Does mental health deserve care or not? The Boston Globe, January 30, 2000, p. C5.

    Google Scholar 

  5. Leslie DL, Rosenheck R. Shifting to outpatient care? Mental health care use and cost under private insurance. American Journal of Psychiatry. 1999; 156:1250-57.

    Google Scholar 

  6. Issue brief, The cost and availability of prescription drugs — what can we do in Massachusetts? The Massachusetts Health Policy Forum, May 12, 1999.

  7. Sager A. Winning affordable medication for everyone. Address to the Massachusetts Health Council, March 5, 1999.

  8. Soumerai SB, McLaughlin TJ, Ross-Degnan D, Casteris CS, Bollini P. Effects of limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. New England Journal of Medicine. 1994; 331:650-55.

    Google Scholar 

  9. Soumerai SB, Ross-Degnan D. Inadequate prescription-drug coverage for Medicare enrollees: A call to action. New England Journal of Medicine. 1999; 340:722-28.

    Google Scholar 

  10. Candilis P, Pollack MH. The hidden costs of untreated anxiety disorders. Harvard Review of Psychiatry. 1997; 5:40-42.

    Google Scholar 

  11. Silverstein K. Millions for Viagra, pennies for diseases of the poor: Research money goes to profitable lifestyle drugs. The Nation. July 19, 1999; 269(3):13.

    Google Scholar 

  12. Baird PA. Funding medical and health-related research in the public interest. Canadian Medical Association Journal. 1996; 155:299-301.

    Google Scholar 

  13. Pharmaceutical Research and Manufacturers of America. Industry Profile, Washington, D.C.: 1998.

  14. Office of Technology Assessment, Pharmaceutical research and development: Costs, risks, and rewards. Washington, D.C.: February, 1993.

  15. Minority Staff Report, Committee on Government Reform, U.S. House of Representatives, Washington, D.C.: July, 1999.

  16. Hotchkiss BD, Pearson C, Lisitano R. Pharmacy coordination of an indigent care program in a psychiatric facility. American Journal of Health-System Pharmacy. 1998; 55:1293-96.

    Google Scholar 

  17. Rawls J. A Theory of Justice. Cambridge, MA: Harvard University Press; 1971.

    Google Scholar 

  18. Decane BE, Chapman J. Program for procurement of drugs for indigent patients. American Journal of Hospital Pharmacy. 1994; 51:669-71.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of Massachusetts Medical School, USA

    Philip J. Candilis

Authors
  1. Philip J. Candilis
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Candilis, P.J. Organizational Ethics and the High Cost of Medicines. HEC Forum 12, 303–310 (2000). https://doi.org/10.1023/A:1008972917960

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1008972917960